BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28716439)

  • 21. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney.
    Aydin H; Chen L; Cheng L; Vaziri S; He H; Ganapathi R; Delahunt B; Magi-Galluzzi C; Zhou M
    Am J Surg Pathol; 2010 Nov; 34(11):1608-21. PubMed ID: 20924276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
    Vokshi BH; Davidson G; Tawanaie Pour Sedehi N; Helleux A; Rippinger M; Haller AR; Gantzer J; Thouvenin J; Baltzinger P; Bouarich R; Manriquez V; Zaidi S; Rao P; Msaouel P; Su X; Lang H; Tricard T; Lindner V; Surdez D; Kurtz JE; Bourdeaut F; Tannir NM; Davidson I; Malouf GG
    Nat Commun; 2023 May; 14(1):3034. PubMed ID: 37236926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
    Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
    Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal medullary carcinoma in a white adolescent with sickle cell trait.
    Daher P; Bourgi A; Riachy E; Khoury A; Rehayem C; Sader-Ghorra C
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):e285-9. PubMed ID: 24517963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal medullary carcinoma involving serous cavity fluids: a cytomorphologic study of 12 cases.
    Miller DL; Ribeiro EA; Roy-Chowdhuri S; Illei PB; Siddiqui MT; Ali SZ
    J Am Soc Cytopathol; 2021; 10(2):187-196. PubMed ID: 32651128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
    Carter SA; Walker AN
    J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications.
    Swartz MA; Karth J; Schneider DT; Rodriguez R; Beckwith JB; Perlman EJ
    Urology; 2002 Dec; 60(6):1083-9. PubMed ID: 12475675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas.
    Seo AN; Yoon G; Ro JY
    Adv Anat Pathol; 2017 Mar; 24(2):65-77. PubMed ID: 28181950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal Medullary Carcinoma: a Report of the Current Literature.
    Blas L; Roberti J; Petroni J; Reniero L; Cicora F
    Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications.
    Lee LH; Yantiss RK; Sadot E; Ren B; Calvacanti MS; Hechtman JF; Ivelja S; Huynh B; Xue Y; Shitilbans T; Guend H; Stadler ZK; Weiser MR; Vakiani E; Gönen M; Klimstra DS; Shia J
    Hum Pathol; 2017 Apr; 62():74-82. PubMed ID: 28034727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor.
    Aron M; Chang E; Herrera L; Hes O; Hirsch MS; Comperat E; Camparo P; Rao P; Picken M; Michal M; Montironi R; Tamboli P; Monzon F; Amin MB
    Am J Surg Pathol; 2015 Jul; 39(7):873-88. PubMed ID: 25970682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of morphologically unclassified renal cell carcinoma with electron microscopy and novel renal markers: implications for tumor reclassification.
    Talento R; Hewan-Lowe K; Yin M
    Ultrastruct Pathol; 2013 Feb; 37(1):70-6. PubMed ID: 23383617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal medullary carcinoma metastatic to the orbit: a clinicopathologic report.
    Zdinak LA; Nik NA; Hidayat AA; Hargett NA
    Ophthalmic Plast Reconstr Surg; 2004 Jul; 20(4):322-5. PubMed ID: 15266151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma.
    Elwood H; Chaux A; Schultz L; Illei PB; Baydar DE; Billis A; Sharma R; Argani P; Epstein JI; Netto GJ
    Urology; 2011 Aug; 78(2):474.e1-5. PubMed ID: 21705046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
    Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mixed adenoneuroendocrine carcinoma of gastrointestinal tract: report of two cases.
    Gurzu S; Kadar Z; Bara T; Bara T; Tamasi A; Azamfirei L; Jung I
    World J Gastroenterol; 2015 Jan; 21(4):1329-33. PubMed ID: 25632209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal medullary carcinoma: an aggressive neoplasm in patients with sickle cell trait.
    Pickhardt PJ
    Abdom Imaging; 1998; 23(5):531-2. PubMed ID: 9841069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts].
    Agaimy A; Hartmann A
    Pathologe; 2021 Nov; 42(6):571-577. PubMed ID: 34609565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal cell carcinoma with rhabdoid features.
    Gökden N; Nappi O; Swanson PE; Pfeifer JD; Vollmer RT; Wick MR; Humphrey PA
    Am J Surg Pathol; 2000 Oct; 24(10):1329-38. PubMed ID: 11023094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
    Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
    BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.